EA200100346A1 - Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль - Google Patents

Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль

Info

Publication number
EA200100346A1
EA200100346A1 EA200100346A EA200100346A EA200100346A1 EA 200100346 A1 EA200100346 A1 EA 200100346A1 EA 200100346 A EA200100346 A EA 200100346A EA 200100346 A EA200100346 A EA 200100346A EA 200100346 A1 EA200100346 A1 EA 200100346A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
capsule
tablet
thickener
optionally
Prior art date
Application number
EA200100346A
Other languages
English (en)
Other versions
EA004443B1 (ru
Inventor
Нареш Тэлвар
Химадри Сен
Джон Стейнифорс
Original Assignee
Рэнбэкси Лабораториз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Рэнбэкси Лабораториз Лимитед filed Critical Рэнбэкси Лабораториз Лимитед
Publication of EA200100346A1 publication Critical patent/EA200100346A1/ru
Publication of EA004443B1 publication Critical patent/EA004443B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Фармацевтическая композиция в форме таблеток или капсул, обеспечивающая сочетание временного и пространственного контроля доставки лекарственного средства пациенту для получения эффективных терапевтических результатов. Фармацевтическая композиция содержит лекарственное средство, газообразующий компонент, агент, вызывающий набухание, загуститель и необязательно гелеобразующий полимер. Агент, вызывающий набухание, относится к классу соединений, известных как супердезинтеграторы (например, сшитый поливинилпирролидон или карбоксиметилцеллюлоза натрия). Загуститель в начальной стадии и гелеобразующий полимер впоследствии формируют гидратированную гелевую основу, которая захватывает газ, вынуждая таблетку или капсулу всплывать, таким образом таблетка или капсула удерживаются в желудке или в верхних участках тонкой кишки (пространственный контроль). В то же время гидратированная гелевая основа создает извилистый путь диффузии для лекарственного средства, приводя к длительному высвобождению лекарственного средства (временной контроль). Предпочтительная ципрофлоксациновая лекарственная форма, принимаемая один раз в день, содержит 69,9% основания ципрофлоксацина, 0,34% альгината натрия, 1,03% ксантановой камеди, 13,7% бикарбоната натрия, 12,1% сшитого поливинилпирролидона и необязательно другие фармацевтические наполнители, причем лекарственная форма имеет форму таблетки или капсулы с покрытием или без покрытия.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100346A 1998-09-14 1999-01-19 Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день EA004443B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control
PCT/IB1999/000078 WO2000015198A1 (en) 1998-09-14 1999-01-19 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (2)

Publication Number Publication Date
EA200100346A1 true EA200100346A1 (ru) 2001-10-22
EA004443B1 EA004443B1 (ru) 2004-04-29

Family

ID=22545063

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200100346A EA004443B1 (ru) 1998-09-14 1999-01-19 Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день
EA200300847A EA005767B1 (ru) 1998-09-14 1999-01-19 Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200300847A EA005767B1 (ru) 1998-09-14 1999-01-19 Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль

Country Status (41)

Country Link
EP (2) EP1281397A1 (ru)
JP (1) JP2002524494A (ru)
CN (1) CN1186013C (ru)
AP (1) AP1659A (ru)
AR (1) AR022672A1 (ru)
AT (1) ATE245414T1 (ru)
AU (1) AU758324B2 (ru)
BG (1) BG105339A (ru)
BR (1) BR9913696A (ru)
CA (1) CA2343760A1 (ru)
CO (1) CO5130022A1 (ru)
CU (1) CU23040A3 (ru)
CZ (1) CZ2001901A3 (ru)
DE (1) DE69909801T2 (ru)
DK (1) DK1107741T3 (ru)
EA (2) EA004443B1 (ru)
EE (1) EE200100153A (ru)
ES (1) ES2204098T3 (ru)
GE (1) GEP20043216B (ru)
HK (1) HK1037967A1 (ru)
HR (1) HRP20010187B1 (ru)
HU (1) HUP0103632A3 (ru)
ID (1) ID29843A (ru)
IL (1) IL141977A0 (ru)
IS (1) IS5885A (ru)
MX (1) MXPA01002634A (ru)
MY (1) MY127952A (ru)
NO (1) NO20011276L (ru)
NZ (2) NZ510487A (ru)
OA (1) OA11652A (ru)
PE (1) PE20001058A1 (ru)
PL (1) PL346798A1 (ru)
PT (1) PT1107741E (ru)
SI (1) SI1107741T1 (ru)
SK (1) SK285478B6 (ru)
SV (1) SV1999000152A (ru)
TR (1) TR200100731T2 (ru)
UA (1) UA73287C2 (ru)
UY (1) UY25710A1 (ru)
WO (1) WO2000015198A1 (ru)
ZA (1) ZA995839B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009374A (ko) * 2000-03-03 2003-01-29 랜박시 래보러터리스 리미티드 시프로플록사신의 1일 1회 투여를 위한 경구 투여용제어된 전달 시스템
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6861071B2 (en) * 2000-08-08 2005-03-01 Daiichi Pharmaceutical Co., Ltd. Highly absorptive solid preparation
IN192748B (ru) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
CA2431205C (en) 2000-12-05 2005-08-23 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
MXPA03012041A (es) 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
PL368327A1 (en) * 2001-08-16 2005-03-21 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
AU2002351798A1 (en) * 2001-10-29 2003-05-12 Labopharm Inc. Methods and dosage forms for improving the bioavailability of therapeutic agents
RU2322263C2 (ru) * 2001-11-13 2008-04-20 Астеллас Фарма, Инк. Система продолжительного высвобождения растворимого лекарственного средства
PT1461017E (pt) 2001-11-19 2006-07-31 Lupin Ltd Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2010020098A1 (zh) 2008-08-18 2010-02-25 北京天衡药物研究院 胃滞留药物释出系统及其制备方法和用途
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
US11504324B2 (en) 2014-11-19 2022-11-22 DuPont Nutrition USA, Inc. Nanosuspension formulation
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
CN110996922A (zh) 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 用于持续药物递送的胃滞留剂型
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
WO2020006278A1 (en) 2018-06-27 2020-01-02 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
MXPA01002634A (es) 2002-06-04
EE200100153A (et) 2002-06-17
EP1281397A1 (en) 2003-02-05
NZ510487A (en) 2003-04-29
HK1037967A1 (en) 2002-03-01
EA200300847A1 (ru) 2003-12-25
TR200100731T2 (tr) 2001-06-21
DE69909801D1 (de) 2003-08-28
AU758324B2 (en) 2003-03-20
PT1107741E (pt) 2003-12-31
ES2204098T3 (es) 2004-04-16
NZ523747A (en) 2004-04-30
PL346798A1 (en) 2002-02-25
CA2343760A1 (en) 2000-03-23
ZA995839B (en) 2000-03-28
CN1186013C (zh) 2005-01-26
HRP20010187B1 (en) 2004-04-30
PE20001058A1 (es) 2000-10-05
DE69909801T2 (de) 2004-06-03
CO5130022A1 (es) 2002-02-27
IL141977A0 (en) 2002-03-10
EA004443B1 (ru) 2004-04-29
CU23040A3 (es) 2005-04-14
UY25710A1 (es) 2000-03-31
AP2001002098A0 (en) 2001-03-31
EP1107741A1 (en) 2001-06-20
ATE245414T1 (de) 2003-08-15
EP1107741B1 (en) 2003-07-23
OA11652A (en) 2004-12-08
SI1107741T1 (en) 2004-02-29
HUP0103632A2 (hu) 2002-02-28
MY127952A (en) 2007-01-31
CN1325299A (zh) 2001-12-05
GEP20043216B (en) 2004-04-26
SK285478B6 (sk) 2007-02-01
AP1659A (en) 2006-09-06
WO2000015198A1 (en) 2000-03-23
SK3472001A3 (en) 2001-10-08
JP2002524494A (ja) 2002-08-06
UA73287C2 (en) 2005-07-15
NO20011276D0 (no) 2001-03-13
AU1779499A (en) 2000-04-03
HRP20010187A2 (en) 2002-04-30
BR9913696A (pt) 2001-10-09
DK1107741T3 (da) 2003-11-17
AR022672A1 (es) 2002-09-04
CZ2001901A3 (cs) 2001-08-15
NO20011276L (no) 2001-05-10
ID29843A (id) 2001-10-18
BG105339A (en) 2001-11-30
EA005767B1 (ru) 2005-06-30
SV1999000152A (es) 2000-07-03
IS5885A (is) 2001-03-12
HUP0103632A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
EA200100346A1 (ru) Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
MXPA01005370A (es) Sistema de matriz de liberacion sostenida para farmacos altamente solubles.
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DK0797435T3 (da) Matrice til kontrolleret frigivelse af lægemidler
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
US20020081332A1 (en) Controlled release formulation of erythromycin or a derivative thereof
DE69928554D1 (de) Therapeutische formulierung enthaltende dosierungsform
CZ2003199A3 (cs) Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
IE940953L (en) Slow release pharmaceutical composition
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
CA2363123A1 (en) Solid oral dosage form containing an enhancer
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
JP2646170B2 (ja) 徐放性塩酸オキシブチニン製剤
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
ECSP993138A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
MXPA04004035A (es) Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.
TH50543A3 (th) ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU